Mobile-health shares surge 26.07% after-hours as clinical trial shows YES mHealth tool improves quality of life for young breast cancer survivors.

Mobile-health surged 26.07% in after-hours trading following the announcement of a groundbreaking mobile health (mHealth) intervention for adolescent and young adult breast cancer survivors. The study, presented at the San Antonio Breast Cancer Symposium, demonstrated that the YES mHealth tool significantly improved general and cancer-specific quality of life scores compared to usual care, with statistically significant results for symptoms like vaginal and arm problems. The tool’s scalability and low-touch model—delivering tailored support via ePROs without direct clinician input—position it as a transformative solution in post-treatment cancer care. The second news event, a local flu vaccination campaign, is unrelated to the stock’s core business. The sharp after-hours rally aligns with the study’s implications for expanding mHealth adoption in oncology, highlighting the tool’s potential to address unmet needs in survivorship care.